Indoco remedies Limited has submitted its quarterly compliance certificate to stock exchanges, fulfilling regulatory requirements under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31st March, 2026.

Regulatory Compliance Filing

The pharmaceutical company filed the mandatory compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 with both the National Stock Exchange of India Limited and Bombay Stock Exchange Limited on April 09, 2026.

Certificate Confirmation

MUFG Intime India Private Limited, formerly Link Intime India Private Limited, serving as the company's registrar and transfer agent, issued the compliance certificate on April 3, 2026. The certificate confirms adherence to dematerialisation requirements during the quarter.

The registrar confirmed that:

• Securities received from depository participants for dematerialisation during Q4 FY26 were properly confirmed to depositories
• Security certificates received were mutilated and cancelled after due verification
• Depository names were substituted in the register of members within prescribed timelines
• All securities comprised in the certificates have been listed on stock exchanges where earlier issued securities are listed

Corporate Governance

The filing was signed by Ramanathan Hariharan, Company Secretary & Head-Legal of Indoco Remedies Limited, demonstrating the company's commitment to regulatory compliance and corporate governance standards.

This quarterly compliance certificate represents part of the company's ongoing regulatory obligations to maintain transparency and adherence to SEBI guidelines for listed entities.

Indoco Remedies Limited announced key auditor re-appointments for the upcoming financial year following a board meeting held on March 31, 2026. The pharmaceutical company's board approved the continuation of its existing audit partnerships to ensure regulatory compliance and internal oversight.

Board Meeting Decisions

The board meeting, which commenced at 01:00 p.m. and concluded at 01:16 p.m. on March 31, 2026, focused on auditor appointments for FY2026-27. The directors considered and approved two critical re-appointments under the provisions of Regulation 30 and Part-A of Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Auditor Re-appointments

The company formalized the re-appointment of two key audit firms for the financial year 2026-2027:

Firm Profiles

M/s Joshi Apte and Associates operates as a firm of Cost Accountants with expertise in Cost Accountancy & Auditing, GST, and Income Tax services. The firm brings specialized knowledge in cost audit requirements for pharmaceutical companies.

M/s. Suresh Surana & Associates LLP was established in 1984 and offers comprehensive multi-disciplinary professional services. The chartered accountancy firm provides specialized services designed to meet both immediate and long-term business requirements of clients across various sectors.

Regulatory Compliance

The appointments comply with SEBI regulations, specifically Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024. The company has notified both the National Stock Exchange of India Limited and Bombay Stock Exchange Limited about these re-appointments as required under regulatory guidelines.

The notification was signed by Ramanathan Hariharn, Company Secretary & Head-Legal, ensuring proper documentation and compliance with listing requirements.